{"groups":[{"description":"Dose Level 1; Bendamustine 30 mg/m2 total, Melphalan 200 mg/m2 total (140 mg/m2 total for patients with Creatinine Clearance \\<70 ml/min)\n\nBendamustine: 30 mg/m2 given on day 2 of melphalan\n\nMelphalan: 100 mg/m2 for 2 days (70 mg/m2 for patients with Creatinine Clearance \\<70 ml/min)","id":"FG000","title":"Dose Level 1"},{"description":"Dose Level 2; Bendamustine 60 mg/m2 total, Melphalan 200 mg/m2 total (140 mg/m2 total for patients with Creatinine Clearance \\<70 ml/min)\n\nMelphalan: 100 mg/m2 for 2 days (70 mg/m2 for patients with Creatinine Clearance \\<70 ml/min)\n\nBendamustine: 60 mg/m2 given on the 2nd day of melphalan","id":"FG001","title":"Dose Level 2"},{"description":"Dose Level 3; Bendamustine 90 mg/m2 total, Melphalan 200 mg/m2 total (140 mg/m2 total for patients with Creatinine Clearance \\<70 ml/min)\n\nMelphalan: 100 mg/m2 for 2 days (70 mg/m2 for patients with Creatinine Clearance \\<70 ml/min)\n\nBendamustine: 90 mg/m2 given on the 2nd day of melphalan","id":"FG002","title":"Dose Level 3"},{"description":"Dose Level 4; Bendamustine 120 mg/m2 total, Melphalan 200 mg/m2 total (140 mg/m2 total for patients with Creatinine Clearance \\<70 ml/min)\n\nMelphalan: 100 mg/m2 for 2 days (70 mg/m2 for patients with Creatinine Clearance \\<70 ml/min)\n\nBendamustine: 60 mg/m2 given on the 1st and 2nd day of melphalan","id":"FG003","title":"Dose Level 4"},{"description":"Dose Level 5; Bendamustine 150 mg/m2 total, Melphalan 200 mg/m2 total (140 mg/m2 total for patients with Creatinine Clearance \\<70 ml/min)\n\nMelphalan: 100 mg/m2 for 2 days (70 mg/m2 for patients with Creatinine Clearance \\<70 ml/min)\n\nBendamustine: 90 mg/m2 given on the 1st day of melphalan and 60 mg/m2 given on the 2nd day of melphalan","id":"FG004","title":"Dose Level 5"},{"description":"Dose Level 6; Bendamustine 225 mg/m2 total, Melphalan 200 mg/m2 total (140 mg/m2 total for patients with Creatinine Clearance \\<70 ml/min)\n\nMelphalan: 100 mg/m2 for 2 days (70 mg/m2 for patients with Creatinine Clearance \\<70 ml/min)\n\nBendamustine: 125 mg/m2 given on the 1st day of melphalan and 100mg/m2 given on the 2nd day of melphalan","id":"FG005","title":"Dose Level 6"},{"description":"Bendamustine 225 mg/m2 total, Melphalan 200 mg/m2 total (140 mg/m2 total for patients with Creatinine Clearance \\<70 ml/min)\n\nMelphalan: 100 mg/m2 for 2 days (70 mg/m2 for patients with Creatinine Clearance \\<70 ml/min)\n\nBendamustine: 125 mg/m2 given on the 1st day of melphalan and 100mg/m2 given on the 2nd day of melphalan","id":"FG006","title":"Phase 2"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"}],"type":"Screen Failure"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"8"},{"groupId":"FG006","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"7"},{"groupId":"FG006","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Phase 1"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"3"}],"type":"Screen Failure"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"31"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"28"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"3"}],"type":"NOT COMPLETED"}],"title":"Phase 2"}],"preAssignmentDetails":"Four subjects were ineligible and therefore never started treatment."}